Valeant Pharmaceuticals – VRX – Agrees To Acquire OraPharma

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that Valeant has agreed to acquire OraPharma, a specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry.

Total consideration is approximately $312 million and up to $114 million in potential contingent payments based on certain milestones, including revenue targets. OraPharma’s lead product is Arestin, a locally administered antibiotic for the treatment of periodontitis that utilizes an advanced controlled-release delivery system and is indicated for use in conjunction with scaling and root planing for the treatment of adult periodontitis.

OraPharma currently has the largest specialized pharmaceutical salesforce in the dental industry and, as of March 31^st, 2012, OraPharma’s trailing twelve month net revenue was approximately $95 million with the business growing at a high single digit rate.

The transaction is expected to close in June 2012, subject to the satisfaction of certain closing conditions, and is expected to be accretive in 2012.

“We are excited to enter a new attractive market segment with an already established sales infrastructure focused entirely on the dental community,” said J. Michael Pearson, chairman and chief executive officer. “We believe that this market segment has similar characteristics to the dermatology, podiatry and ophthalmology markets and should offer us the opportunity to cross-sell some of our current products, most notably our new topical prescription cold sore medication, Xerese.  We believe the OraPharma business is a new growth platform from which to build additional opportunities in the future.”

About Valeant Pharmaceuticals International, Inc. – VRX

Valeant Pharmaceuticals International, Inc. (VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.

VRX  was formerly Biovail Corporation.  VRX operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics – Europe and Branded Generics -Latin America. On December 12, 2011, it acquired assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, Inc. (Janssen). On December 16, 2011, it acquired the dermatology business, Dermik, of Sanofi. On December 21, 2011, it acquired iNova, from Archer Capital, Ironbridge Capital and other minority management shareholders. On February 1, 2012, it acquired Probiotica Laboratorios Ltda. On February 3, 2012, it divested 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), and 5% fluorouracil cream, (5-FU). On March 12, 2012, it acquired a 19.9% interest in Pele Nova Biotecnologia S.A. In April 2012, it acquired Pedinol Pharmacal, Inc.

More Posts by this author

• Gold Prices Settle Higher
• Stocks End Sharply Higher for a Second Straight Day
• Stocks Continue to Rally
• Cinedigm Digital Cinema – CIDM – Fiscal 2012 marked a successful strategic transformation of the Company
• Wabtec – WAB – Acquires Mors Smitt
• Gold and Silver Prices Hold on to Gains
• Investors Bancorp – ISBC – To Acquire Marathon Banking Corporation from Piraeus Bank S.A.

Post Written By: Ed Liston Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.